Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 13/20 | 0.42 |
| ▸ | EDNRB | P24530 | 12/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7912693 | 0.81 | SLC40A1 (0.47) | EDNRAEDNRBALDH1A1KDM4EGAA | |
| SCHEMBL25836464 | 0.80 | ALDH1A1 (0.39) | EDNRAEDNRBALDH1A1KDM4ELMNA | |
| SCHEMBL21885975 | 0.79 | CHRM2 (0.43) | EDNRAALDH1A1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL758126 | 0.79 | CA12 (0.55) | ALDH1A1KDM4ELMNAGAAMAPT | |
| SCHEMBL10105631 | 0.78 | CHRNA7 (0.45) | EDNRAEDNRBALDH1A1KDM4ELMNA | |
| SCHEMBL1040641 | 0.77 | CHRNA7 (0.38) | EDNRAEDNRBALDH1A1KDM4ELMNA | |
| SCHEMBL5002545 | 0.77 | FABP3 (0.40) | EDNRAEDNRBALDH1A1KDM4ELMNA | |
| SCHEMBL6179639 | 0.77 | CA12 (0.55) | EDNRAALDH1A1KDM4ELMNAGAA | |
| SCHEMBL1037832 | 0.76 | ALDH1A1 (0.44) | EDNRAALDH1A1LMNAGAAMAPT | |
| SCHEMBL12186143 | 0.75 | CHRNA7 (0.38) | EDNRAEDNRBALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | EDNRA 2354/4885EDNRB 2375/4885ALDH1A1 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.